Charlotte, N.C. – Bourne Partners (“Bourne”), a leading healthcare-focused investment bank, is excited to announce the appointment of Ryan Silvester as Vice President, PharmaTech & Healthcare Technology. With his extensive industry knowledge and experience in private equity investing and M&A advisory, Mr. Silvester will provide a unique perspective to help Bourne’s clients achieve exceptional outcomes. Ryan will play a key role in expanding Bourne’s coverage in the pharma technology, tech-enabled pharma services, and life sciences software sub-sectors, as well as the broader healthcare technology and digital health space. Mr. Silvester will be responsible for leading project execution and negotiations of sell-side and buy-side M&A and capital raise engagements for Bourne’s global client base.

Most recently, Ryan was a Senior Associate at Ballast Point Ventures (“BPV”), a growth equity firm focused on investing in software, healthcare, and tech-enabled services businesses. While at BPV, Ryan spent his time originating and evaluating investment opportunities, assisting portfolio company management teams with strategy and growth initiatives, and managing Limited Partner communications. Prior to joining BPV, Ryan was an Investment Banking Associate at Crosstree Capital Partners (“Crosstree”), where he focused on providing sell-side and buy-side M&A advisory and capital raising services to private and public companies within the pharma services, digital health, and life sciences tools and diagnostics industries. Before Crosstree, Ryan was an Investment Banking Analyst in the M&A group at SunTrust Robinson Humphrey, now known as Truist Securities.

“Ryan is a solid addition to our growing team at Bourne Partners. His background and track record will allow him to bring a truly unique perspective and level of insight to our clients,” said Jeremy Johnson, Head of Investment Banking at Bourne Partners. “In addition to having considerable transaction experience across a variety of software and tech-enabled healthcare companies, Ryan has been both the M&A advisor to clients and more recently a private equity investor. This experience and 360-degree perspective afford him insights uncommon among M&A advisors. We are thrilled to have him join our team and help us continue to build Bourne into the industry leading healthcare investment bank.”

“Bourne Partners’ dedication and passion for delivering exemplary M&A advisory and investment banking services are truly inimitable,” said Mr. Silvester. “I look forward to joining the talented, dynamic team and working closely with my colleagues and the firm’s clients to deliver extraordinary results and further strengthen Bourne’s position as a world-class leader in the industry.”

Bourne is proud to have a team of highly experienced M&A professionals, all dedicated to serving clients within pharmaceuticals, pharmaceutical services, consumer health, and healthcare services sectors. With their collective expertise and deep industry knowledge, Bourne is well-positioned as the premier M&A advisory firm, offering world-class guidance to clients navigating complex business challenges. This strong leadership team is a testament to our commitment to excellence and our ability to deliver superior service and outcomes for our clients.

About Bourne Partners

Bourne Partners is a financial services firm specializing in the pharma, pharma services, consumer health, and healthcare services sectors. Located in Charlotte, North Carolina, the company offers investment banking and transaction advisory services. As owners and operators with over 20 years of experience, Bourne Partners strives to enrich the lives and improve the health and well-being of their partners and patients by facilitating the efficient movement of capital through the global healthcare sector. For more information, please visit here.